Uroonkologische und nuklearmedizinische Behandlungsmöglichkeiten beim metastasierten, kastrationsresistenten Prostatakarzinom (mCRPC)

• Literatur

• 1 Heidenreich A, Bastian PJ, Bellmunt J. et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014; 65: 467-79
• 2 Geethakumari PR, Cookson MS, Kelly WK. et al. The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Oncol Williston Park N 2016; 30 187-195 , 199
• 3 Eisenhauer EA, Therasse P, Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl 1990 2009; 45: 228-47
• 4 Hussain M, Fizazi K, Saad F. et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 2018; 378: 2465-74
• 5 Smith MR, Saad F, Chowdhury S. et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med 2018; 378: 1408-18
• 6 Ryan CJ, Smith MR, de Bono JS. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138-48
• 7 Rathkopf DE, Smith MR, de Bono JS. et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol 2014; 66: 815-25
• 8 de Bono JS, Logothetis CJ, Molina A. et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005
• 9 Beer TM, Armstrong AJ, Rathkopf DE. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424-33
• 10 Scher HI, Fizazi K, Saad F. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-97
• 11 Petrylak DP, Tangen CM, Hussain MHA. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20
• 12 Tannock IF, de Wit R, Berry WR. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12
• 13 Kellokumpu-Lehtinen P-L, Harmenberg U, Joensuu T. et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 2013; 14: 117-24
• 14 Sweeney C, Chen Y-H, Carducci MA. et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J Clin Oncol 2014; 32: LBA2-LBA2
• 15 de Bono JS, Oudard S, Ozguroglu M. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet Lond Engl 2010; 376: 1147-54
• 16 Eisenberger M, Hardy-Bessard A-C, Kim CS. et al. Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m²) and the Currently Approved Dose (25 mg/m²) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. J Clin Oncol Off J Am Soc Clin Oncol 2017; 35: 3198-206
• 17 Parker C, Nilsson S, Heinrich D. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-23
• 18 Updated survival, quality of life (QOL),. and safety data of radium-223 chloride (RA-223) in patients with castrationresistant prostate cancer (CRPC) with bone metastases from the phase 3 double-blind, randomized, multinational study (ALSYMPCA). ResearchGate Available from: [cited 2019 Feb 11] https://www.researchgate.net/publication/284906061_Updated_survival_quality_of_life_QOL_and_safety_data_of_radium-223_chloride_RA-223_in_patients_with_castration-resistant_prostate_cancer_CRPC_with_bone_metastases_from_the_phase_ 3_double-blind_randomi
• 19 BfArM – Rote-Hand-Briefe und Informationsbriefe – Radium-223-dichlorid (Xofigo®): Neue Einschränkungen für den Gebrauch aufgrund von erhöhtem Frakturrisiko und einem Trend zu erhöhter Mortalität. [cited 2019 Feb 11] Available from: https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2018/rhb-xofigo2.html [Internet]
• 20 Smith MR, Parker CC, Saad F, Miller K, Tombal B, Ng QS. et al. LBA30ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone / prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bonepredominant metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol; Available from: 2018: 29. https://academic.oup.com/annonc/article/29/suppl_8/mdy424.035/5141747 [cited 2019 Feb 11] [Internet]
• 21 Heck MM, Retz M, Tauber R. et al. PSMA-targeted radioligand therapy in prostate cancer. Urol Ausg A 2017; 56: 32-9
• 22 von Eyben FE, Roviello G, Kiljunen T. et al. Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging 2018; 45: 496-508
• 23 Heck MM, Tauber R, Schwaiger S. et al. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. Eur Urol 2018 : doi: 10.1016 / j.eururo.2018.11.016
• 24 Rahbar K, Ahmadzadehfar H, Kratochwil C. et al. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J Nucl Med Off Publ Soc Nucl Med 2017; 58: 85-90
• 25 Hofman MS, Violet J, Hicks RJ. et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castrationresistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 2018; 19: 825-33
• 26 Kratochwil C, Bruchertseifer F, Rathke H. et al. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding. J Nucl Med Off Publ Soc Nucl Med 2017; 58: 1624-31